Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?
Tóm tắt
Currently, there is no consensus regarding which patients with high-risk prostate cancer (PCa) would benefit the most by radical prostatectomy (RP). We aimed to identify patients with high-risk PCa who are treatable by RP alone. We retrospectively reviewed data on 315 patients with D’Amico high-risk PCa who were treated using RP without neoadjuvant or adjuvant therapy at the institutions of the Yamaguchi Uro-Oncology Group between 2009 and 2013. The primary endpoint was biochemical progression-free survival (bPFS) after RP. Risk factors for biochemical progression were extracted using the Cox proportional hazard model. We stratified the patients with high-risk PCa into 3 subgroups based on bPFS after RP using the risk factors. At a median follow-up of 49.9 months, biochemical progression was observed in 20.5% of the patients. The 2- and 5-year bPFS after RP were 89.4 and 70.0%, respectively. On multivariate analysis, Gleason score (GS) at biopsy (≥ 8, HR 1.92, p < 0.05) and % positive core (≥ 30%, HR 2.85, p < 0.005) were independent predictors of biochemical progression. Patients were stratified into favorable- (0 risk factor; 117 patients), intermediate- (1 risk factor; 127 patients), and poor- (2 risk factors; 57 patients) risk groups, based on the number of predictive factors. On the Cox proportional hazard model, this risk classification model could significantly predict biochemical progression after RP (favorable-risk, HR 1.0; intermediate-risk, HR 2.26; high-risk, HR 5.03; p < 0.0001). The risk of biochemical progression of high-risk PCa after RP could be stratified by GS at biopsy (≥ 8) and % positive core (≥ 30%).
Tài liệu tham khảo
Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629
Yossepowitch Eggener SE, Bianco FJ Jr et al (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178(2):493–499
Briganti A, Karnes RJ, Gandaglia G et al (2015) Natural history of surgically treated high-risk prostate cancer. Urol Oncol 33(4):163.e7–163.e13
Rider JR, Sandin F, Andrén O et al (2013) Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 63(1):88–96
Ploussard G, Masson-Lecomte A, Beauval J-B et al (2011) Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification. Urology 78(3):607–613
Joniau S, Briganti A, Gontero P et al (2015) Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol 67(1):157–164
Sobin LH, Gospodarowicz MK, Wittekind Ch et al (2009) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, London
Kobayashi T, Kimura T, Lee C et al (2016) Subclassification of high-risk clinically organ-confined prostate cancer for early cancer-specific mortality after radical prostatectomy. Jpn J Clin Onocol 46(8):762–767
Loeb S, Schaeffer EM, Trock BJ et al (2010) What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 76(3):710–714
Sundi D, Wang V, Pierorazio PM et al (2014) Identification of men with the highest risk of early disease recurrence after radical prostatectomy. Prostate 74(6):628–636
Walz J, Joniau S, Chun FK et al (2011) Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 107(5):765–770
Hamada R, Nakashima J, Ohori M et al (2016) Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer. Int J Clin Oncol 21(3):595–600
Yuasa T, Maita S, Tsuchiya N et al (2010) Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75(5):1131–1137
Tendulkar RD, Reddy CA, Stephans KL et al (2012) Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy. Int J Radiat Oncol Biol Phys 82(4):1397–1404
Spalding AC, Daignault S, Sandler HM et al (2007) Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation. Urology 69(5):936–940
Briganti A, Larcher A, Abdollah F et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61(3):480–487
Fossati N, Willemse P-PM, van den Broeck T et al (2017) The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol 72(1):84–109